This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Lamictal pay-for-delay case sent back to New Jersey federal court

By Leah Nylen ( July 2, 2013, 20:29 GMT | Insight) -- A US appeals court has sent back a case over an alleged pay-for-delay agreement between GlaxoSmithKline and Teva on epilepsy drug Lamictal for the lower court to reconsider its dismissal of the suit in the wake of the Supreme Court’s recent ruling on analyzing such deals. The move defers a decision by an appellate court on whether so-called no-AG agreements between branded and generic drugmakers are anticompetitive.In the wake of a recent Supreme Court ruling, a US appeals court has asked a lower court to reconsider its dismissal of a suit involving an alleged pay-for-delay agreement between GlaxoSmithKline and Teva related to the epilepsy drug Lamictal....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections